# Supplementary Table 2. There are six trials comparing effect of various strains of BCG including: BCG-Japan, BCG-Russia, BCG-Russia-I (Serum Institute of India), BCG-Denmark 1331, BCG-Tice, BCG- Connaught, BCG-Tokyo-172, BCG-Denmark culture (SSI), on Heterologous Immunity, Infant Morbidity, Infant Mortality, Trained Immunity, Vaccine Reaction, and Bladder Urothelial Carcinoma.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Project** | **Condition or disease** | **Intervention/treatment** | **Phase** | **Saple size** | **Result** |
| Bandim Health Project, University of Southern Denmark**NCT04383925****Ref. # 18** | Death, InfantMorbidity, Infant | BCG-JapanBCG-Russia | Phase 4 | 15000 participants | Estimated Study Completion Date: December 2022 |
| Bandim Health Project, Statens Serum Institut**NCT02447536****Ref. # 19** | MorbidityBacille Calmette-Guérin | BCG-Denmark 1331 (Statens Serum Institute)BCG-Russia-I (Serum Institute of India) | Phase 4 | 12006 participants | BCG strains did not affect morbidity. BCG-Denmark and BCG-Japan were more immunogenic than BCG-Russia by the measures traditionally viewed as surrogates for successful immunization. |
| Bandim Health Project, Research Center for Vitamins and Vaccines**NCT03400878****Ref. # 20** | Heterologous ImmunityInfant MorbidityInfant Mortality Trained Immunity Vaccine Reaction Vaccine Adverse Reaction | BCG-JapanBCG-Russia | Phase 4 | 17505 participants | - |
| Southwest Oncology Group, National Cancer Institute (NCI)**NCT03091660****Ref. # 21** | Stage 0 Bladder Urothelial CarcinomaStage 0is Bladder Urothelial CarcinomaStage I Bladder Urothelial Carcinoma | BCG SolutionBCG Tokyo-172 Strain SolutionBCG Tokyo-172 Strain VaccineLaboratory Biomarker Analysis | Phase 3 | 1000 participants | Estimated Study Completion Date: February 2025 |
| Swiss Group for Clinical Cancer Research**NCT00003779****Ref. # 22** | Bladder Cancer | ConnaughtTice | Phase 3 | 40 participants | treatment with BCG Connaught prevented recurrences more efficiently than BCG Tice. Comparison of the immunogenicity of the two strains in mice indicated superior immunogenicity of BCG Connaught. We also identified genetic differences that may explain the differential efficacy of the Connaught and Tice BCG strains. |
| University of Oxford**NCT00480714****Ref. # 23** | TB | BCG (SSI Strain) | - | 10 participants | In volunteers who had been vaccinated 0.5-38 years previously with BCG, substantially higher levels of antigen-specific IFN-gamma-secreting T cells were induced, and at 24 weeks after vaccination these levels were 5-30 times greater than in vaccinees administered a single BCG vaccination. |